%0 Editorial
%T Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer.
%A Kurozumi S
%A Katayama A
%A Shirabe K
%A Horiguchi J
%A Rakha EA
%J Oncotarget
%V 12
%N 22
%D Oct 2021 26
%M 34733421
暂无%R 10.18632/oncotarget.28007
%X